State of The Art in Multiple Myeloma: Year in Review 2022

home / around-the-practice / state-of-the-art-in-multiple-myeloma-year-in-review-2022

A panel of experts discusses recent advances and key clinical trial data presented at ASH 2022 concerning the treatment of multiple myeloma.

State of The Art in Multiple Myeloma: Year in Review 2022

EP. 1: State of The Art in Multiple Myeloma: Year in Review 2022

December 21st 2022

A video preview for an upcoming program reviewing clinical trial data and updates in the multiple myeloma treatment landscape over the last year.

Experts on MM

EP. 2: Induction Regimen Options in Transplant-Eligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
January 30th 2023

Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.

Experts on MM

EP. 3: DETERMINATION, GRIFFIN, and MASTER Studies

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
January 30th 2023

Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.

Experts on MM

EP. 4: Role of Transplant and Induction Therapies in NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
February 6th 2023

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

Experts on MM

EP. 5: Induction Therapy in Transplant-Ineligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
February 6th 2023

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Experts on MM

EP. 6: Clinical Trials in Transplant-Ineligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
February 13th 2023

Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.

Experts on MM

EP. 7: Review of Patient Subgroups in Transplant-Ineligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
February 13th 2023

Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.

Experts on MM

EP. 8: Final Thoughts on Transplant-Ineligible Patients with MM

Robert Z. Orlowski, MD, PhD;C. Ola Landgren, MD, PhD;Amrita Y. Krishnan, MD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
February 20th 2023

Experts offer final thoughts on the treatment of newly diagnosed MM for patients that are transplant-ineligible.

Expert on MM

EP. 9: Treatment Approaches for Patients with Relapsed-Refractory MM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
February 20th 2023

Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).

Experts on MM

EP. 10: Treatment Selection of Bispecifics in Relapsed-Refractory MM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
February 27th 2023

Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.

Experts on MM

EP. 11: Rationale for Bispecific-Based Combinations in MM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
February 27th 2023

Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.

Experts on MM

EP. 12: The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
March 6th 2023

Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.

Expert on MM

EP. 13: Management of Bispecific Toxicities and Final Thoughts on Treatments in MM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD
March 6th 2023

Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.

Experts in the multiple myeloma space review available therapies such as CAR T-cell therapy, bispecifics, and B-cell maturation antigen–targeted agents for patients with multiple myeloma.

EP. 14: Evaluating Treatment Options by Patient Type in Multiple Myeloma

Ariana Pelosci
April 8th 2023

Experts in the multiple myeloma space review available therapies such as CAR T-cell therapy, bispecifics, and B-cell maturation antigen–targeted agents for patients with multiple myeloma.